CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,113 enrolled
Drug / intervention
RSVPreF3 OA investigational vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05879107
NCT05879107Phase 3Completed
CompareCT.gov

A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older

GlaxoSmithKline·interventional·Posted May 30, 2023·Updated May 18, 2025

In Brief

A Phase 3 clinical trial evaluating RSVPreF3 OA investigational vaccine and PCV20 for Respiratory Syncytial Virus Infections. Completed, enrolled 1,113 participants across 38 sites in 4 countries.

Detailed Summary

The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus Infections
CountriesBelgium, Poland, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMay 30, 2023
Enrollment StartMay 26, 2023
Primary CompletionDec 6, 2023
Study CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.1 years ago

Interventions

RSVPreF3 OA investigational vaccinebiological

One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).

PCV20biological

One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1